Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Feb;26(2):246-51.

Arterial occlusion revealed by CT angiography predicts NIH stroke score and acute outcomes after IV tPA treatment

Affiliations

Arterial occlusion revealed by CT angiography predicts NIH stroke score and acute outcomes after IV tPA treatment

John R Sims et al. AJNR Am J Neuroradiol. 2005 Feb.

Abstract

Background and purpose: The relationship between location of occlusion and clinical outcome is poorly understood in patients receiving intravenous tissue-type plasminogen activator (IV tPA). We postulated that acute stroke patients receiving IV tPA with patent vasculature or occult arterial occlusion by CT angiography (CTA) would have better outcomes and decreased hemorrhagic risk.

Methods: We identified 47 patients from our prospective stroke database who underwent CTA before treatment with IV tPA. Site of occlusion was categorized as M1 segment of the middle cerebral artery, M2 segment, multiple (either carotid, basilar, or both middle and anterior cerebral arteries), or absent (no occlusion proximal to M3). The effect of site of occlusion on National Institutes of Health Stroke Scale (NIHSS), early improvement (> or = 4-point improvement in NIHSS at 24 hours after treatment), intracranial hemorrhages, and modified Rankin scale (mRS) at 7 days was tested in a multivariate analysis.

Results: The location of occlusion correlated with initial NIHSS for multiple, M1, M2 and absent occlusions (median NIHSS scores were 18, 18, 15, 10, respectively) (P < .02, rank sum). Following adjustment for initial NIHSS, age, and time to treatment, the absence of occlusion remained associated with early improvement (OR 5.0, 95% CI 1.1-23.3; P = .04) and independence at day 7 (mRS < or = 2) (OR 6.8, 95% CI 1.3-34.6; P = .02). Overall prevalence of symptomatic hemorrhages was 6.4%. Patients without occlusion had no hemorrhages (0% versus 23.3%; P < .04).

Conclusion: Among patients treated with tPA, those with patent vasculature or occult distal occlusion on CTA before treatment have lower NIHSS, better chances of early improvement and early independence with fewer hemorrhages.

PubMed Disclaimer

Figures

F<sc>ig</sc> 1.
Fig 1.
Site of occlusion predicts early improvement at 24 hours. Those patients without CTA-visualized occlusion proximal to the M3 division have significantly better early improvement (P < .02).
F<sc>ig</sc> 2.
Fig 2.
Those patients without CTA-visualized occlusion proximal to M3 have a significantly better good outcome based on mRs ≤ 2 at 7 days or discharge, whichever came first (P = .01).

References

    1. The National Institute of Neurological Disorders and Stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587 - PubMed
    1. The NINDS t-PA stroke study group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109–2118 - PubMed
    1. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA. 1995;274:1017–1025 - PubMed
    1. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet. 1998;352:1245–1251 - PubMed
    1. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. JAMA. 1999;282:2019–2026 - PubMed

Publication types

Substances